Abbisko Therapeutics

Abbisko Therapeutics, based in Shanghai and listed in Hong Kong, develops small-molecule kinase inhibitors. Its lead drug pimicotinib (ABSK021), a selective CSF-1R inhibitor, met the primary endpoint of the phase 3 MANEUVER trial in tenosynovial giant cell tumour; Merck KGaA exercised its global commercialisation option in April 2025 for a USD 85 million fee. China's regulator approved pimicotinib in December 2025 for adults with symptomatic tenosynovial giant cell tumour where surgery would cause functional limitation or severe morbidity, and the FDA accepted a new drug application in January 2026. FGFR4 and pan-FGFR inhibitors follow in liver and urothelial cancer. Its trials are registered on ClinicalTrials.gov under Abbisko as lead sponsor.